Physician
Oncology
Dr. James C. Yao, MD
|
|
Give Review
Doctor James C. Yao, MD is an expert in the field of Oncology. He studied medicine at Baylor College of Medicine. James is also a published doctor. He has 82 paper published. The most recent paper is: Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
Publications
- Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
- Clinical Trial Design in Neuroendocrine Tumors.
- From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.
- Role and Operative Technique of Portal Venous Tumor Thrombectomy in Patients with Pancreatic Neuroendocrine Tumors.
- Octreotide Long-Acting Repeatable among Elderly Patients with Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data.
- Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials.
- Treatment of Carcinomatosis using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in adolescents and young adults.
- Effect on Perfusion Values of Sampling Interval of Computed Tomographic Perfusion Acquisitions in Neuroendocrine Liver Metastases and Normal Liver.
- Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT...
- Initial treatment of well-differentiated neuroendocrine Tumors.
- Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors.
- Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
- Expression of Estrogen-Induced Genes and Estrogen Receptor β in Pancreatic Neuroendocrine Tumors: Implications for Targeted Therapy.
- Autophagy mediates HIF2α degradation and suppresses Renal tumorigenesis.
- Effect of Pre-Enhancement Set point on Computed Tomographic Perfusion Values in Normal Liver and Metastases to the Liver From Neuroendocrine Tumors.
- Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population-based Analysis.
- Accelerated approval and breakthrough therapy designation: oncology drug development on speed?
- Metastases to the Liver from Neuroendocrine Tumors: Effect of Duration of Scan Acquisition on CT Perfusion Values.
- The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and Cell survival under energy stress.
- Resection of At-Risk Mesenteric Lymph Nodes Is Associated with Improved Survival in Patients with Small Bowel Neuroendocrine Tumors.
- Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors.
- Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned.
- Everolimus in advanced pancreatic neuroendocrine Tumors: the clinical experience.
- Improving the Success Rate of Gluteal Intramuscular Injections.
- The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy.
- Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
- New strategies for advanced neuroendocrine Tumors in the era of targeted therapy.
- Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus.
- Overcoming antiangiogenic resistance.
- Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors.
- Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
- Perfusion CT findings in patients with metastatic carcinoid Tumors undergoing bevacizumab and interferon therapy.
- Thymic neuroendocrine tumors: a SEER database Analysis of 160 patients.
- Trimodality therapy without a platinum compound for localized Carcinoma of the esophagus and gastroesophageal junction.
- Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal Cancer.
- Combined treatment of pancreatic Cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.
- Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine Tumors after failure of cytotoxic chemotherapy: a phase II trial.
- Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric Cancer.
- Glycemic control in patients with insulinoma treated with everolimus.
- Neuroendocrine Tumors: novel approaches in the age of targeted therapy.
- Treatment options for metastatic neuroendocrine Tumors.
- Octreotide LAR in carcinoid: how to dose?
- Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine Tumors: results of a phase II study.
- Risk factors associated with neuroendocrine Tumors: A U.S.-based case-control study.
- The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base.
- One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine Tumors in 35,825 cases in the United States.
- Family history of Cancer and associated risk of developing neuroendocrine tumors: a case-control study.
- Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interfe...
- Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism Analysis and comparison wi...
- Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine Carcinomas after hepatic arterial embolization.
- Population-based study of islet cell Carcinoma.
- Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric Cancer.
- The development and characterization of a human midgut carcinoid Cell line.
- Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine Tumors (pancreatic endocrine Tumors and carcinoid Tumors).
- Molecular targeted therapy for neuroendocrine Tumors.
- Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade ...
- Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric Carcinoma in a multicenter phase II study.
- Clinical and in vitro studies of imatinib in advanced carcinoid Tumors.
- Outcome of gastric Cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival.
- Update on the management of Neuroendocrine hepatic metastases.
- A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroEsophageal junction adenocar...
- Management of pancreatic endocrine Tumors in multiple endocrine neoplasia type 1.
- Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenoCarcinoma.
- Carcinoid Tumors of the duodenum.
- Epigenetic alterations in neuroendocrine Tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis.
- Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine Tumors: variables affecting response rates and survival.
- Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric Carcinoma.
- Comparison of genetic alterations in neuroendocrine Tumors: frequent loss of chromosome 18 in ileal carcinoid Tumors.
- Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: Analysis of a single institution's experience over 15 years.
- Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric Cancer development and progression.
- Surgical treatment of non-functioning pancreatic islet cell Tumors.
- Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of hum...
- Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric Carcinoma.
- Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal Cancer patients.
- Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine Carcinomas.
- Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients w...
- Primary and metastatic hepatic carcinoid: is there an algorithm?
- Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid Tumors: the M.D. Anderson experience.
- Combined-modality therapy for gastric Cancer.
- Adjuvant and preoperative chemotherapy for gastric Cancer.
- A Tale of Two Tumors: Treating Pancreatic and Extrapancreatic Neuroendocrine Tumors.
Schools
Baylor Coll Of Med
Baylor College Of Med
University Tx Med School At Houston
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Baylor College of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1962593376 | |
| NPPES Provider LastName | YAO | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 206.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1962593376 |
| Last Name Of The Provider | YAO |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Paul B. Koller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimberly H. Koenig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mothaffar F. Rimawi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon M. Giordano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sindhu Nair, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert Z. Orlowski, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Theodore F. Tenczynski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jenny V. Pozadzides, MD
This Doctor is OpenDoctor Recommended.
|